通过2型生物标志物预测dupilumab的有效性:对严重喘的现实研究
Kenji Mizumura1, Yasuhiro Gon1, Norihiro Harada2
1Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
概括
杜皮卢马布在现实环境中有效治疗严重喘,改善肺功能和症状. 升高的FeNO和乙氨基酸计数预测在杜皮卢马布治疗患者的治疗结果会更好.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 杜皮卢马布在治疗严重喘时的实际有效性需要进行前性调查.
- 对于重症喘中dupilumab疗效的预测因素尚不清楚.
- 本研究评估dupilumab的有效性,并使用2型生物标志物确定预测因子.
研究的目的:
- 在现实环境中评估dupilumab在严重喘患者的治疗有效性.
- 为了确定dupilumab有效性的预测指标,专注于FeNO和血液中氨酸细胞计数.
- 为了将生物标志物水平与临床结果和呼吸功能改善相关联.
主要方法:
- 在24周内对103名严重喘患者进行了前性多中心研究.
- 监测恶化,呼吸功能 (FEV1),控制喘 (ACQ-5) 和症状 (CASA-Q).
- 基于基线FeNO和血液中乙酸氨基细胞计数的亚组分析;预测因子的回归分析.
主要成果:
- 杜皮卢马布减少了恶化,改善了喘控制,FEV1和CASA-Q分数.
- FEV1的改善与CASA-Q唾液域增强相关.
- 升高的FeNO和乙氨基酸预测了更大的FEV1改善;乙氨基酸预测了唾液改善.
结论:
- 2型生物标志物 (FeNO,乙氨基) 是用dupilumab治疗的严重喘患者FEV1改善的显著预测因素.
- 这些生物标志物可能表明,在现实世界杜皮卢马布治疗中,唾液结果有所改善.
- FeNO和血中乙氨基酸细胞的数量可以指导重症喘中杜皮卢马布的治疗预期.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
246
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
246
Antiasthma Drugs: β2-Adrenoceptor Agonists
239
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
239
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Drugs Used in Lower Respiratory Disorders: Overview
362
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
362
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K


